Zeposia (ozanimod)

A next-generation oral S1P receptor modulator for adults with relapsing forms of MS (clinically isolated syndrome, relapsing-remitting MS and active secondary progressive MS) that offers improved selectivity over fingolimod, potentially reducing cardiac side effects. Also approved for ulcerative colitis.

Like fingolimod, ozanimod traps lymphocytes in lymph nodes by acting on S1P receptors. But ozanimod is more selective, targeting mainly the S1P1 and S1P5 receptor subtypes. S1P1 selectivity is what keeps immune cells sequestered; S1P5 may have additional benefits for the nervous system. By avoiding S1P3 (which affects the heart), ozanimod may have fewer cardiac effects than fingolimod.

Upper respiratory infections, elevated liver enzymes, and low blood pressure when standing up (orthostatic hypotension) are common. Zeposia lowers the number of immune cells in the blood, which raises the risk of infections, some serious, life-threatening or, rarely, fatal, including a rare brain infection called PML that usually causes death or severe disability. A blood count is checked before starting, the infection risk lasts for up to 3 months after stopping, and you should report fever, signs of infection, or new weakness, clumsiness, vision changes or confusion right away. Zeposia may harm an unborn baby, so women who can become pregnant should use effective birth control during treatment and for 3 months after stopping. Does not require first-dose cardiac monitoring like fingolimod, though an ECG is done before starting and a dose escalation over the first week is needed. Macular edema (swelling in the back of the eye) is possible, so an eye exam is recommended near the start of treatment. Serious liver injury, including liver failure needing a transplant, has been reported since approval, so liver tests are checked before starting; report yellowing of the skin or eyes, dark urine, or unusual tiredness. The label also warns about higher blood pressure, reduced lung function, skin cancers (skin checks are recommended before or soon after starting and then regularly), a rare brain swelling condition called PRES, and a severe worsening of MS disability after stopping Zeposia.

Taken as one capsule by mouth once daily. Requires a 7-day dose titration (starting at 0.23 mg, then 0.46 mg, then the full 0.92 mg dose). No first-dose observation period required, unlike fingolimod.

Yes, Ozanimod (Zeposia) is FDA approved (2020) for the treatment of Multiple Sclerosis.

Ozanimod is more selective for S1P1 and S1P5 receptors and avoids S1P3, which is involved in cardiac effects. Additionally, ozanimod uses a 7-day dose escalation (starting at a lower dose and gradually increasing), which allows the heart to adapt gradually. This approach minimizes the risk of clinically significant heart rate slowing, so the FDA does not require the 6-hour first-dose observation that fingolimod needs. However, patients with certain pre-existing cardiac conditions may still need monitoring.

Yes. Ozanimod was approved for moderately to severely active ulcerative colitis in 2021, making it one of the few MS drugs with a dual indication. The same mechanism of trapping immune cells in lymph nodes that reduces brain inflammation in MS also reduces gut inflammation in ulcerative colitis.

Both are S1P receptor modulators that trap lymphocytes in lymph nodes. Ozanimod is more selective (targeting S1P1 and S1P5 only), which may reduce cardiac side effects. Ozanimod does not require first-dose cardiac monitoring and has a shorter dose-escalation period. However, fingolimod is available as a generic at significantly lower cost. Clinical trial designs differed, making direct efficacy comparisons difficult, but both are considered effective for relapsing MS.

The current Zeposia label has no food restrictions. In a tyramine challenge study, ozanimod had no clinically significant effect on the blood pressure response to tyramine, so you do not need to avoid aged cheeses or cured meats. What is not allowed is taking Zeposia with MAO inhibitor medicines such as selegiline, phenelzine or linezolid, and at least 14 days should pass after stopping Zeposia before starting an MAO inhibitor. Tell your doctor about every medicine you take.

Because of the 7-day dose escalation, patients reach the full therapeutic dose on day 8. The drug begins reducing lymphocyte counts within the first week, and clinical effects on relapse reduction are typically seen over the following weeks to months. MRI evidence of reduced disease activity (fewer new lesions) is usually apparent within 3-6 months of starting treatment.